Article
Humira to gain fifth indication?
Abbott Laboratories has received a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted Abbott Laboratories a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis. If fully approved, psoriasis will be the fifth disease indication for Humira, after rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.
Abbott is also hoping for FDA approval for this indication.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
